All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
The EMA grants MRG-106 Orphan Drug Designation for Cutaneous T-Cell Lymphoma
Bookmark this article
On 24th May 2017, the European Medicines Agency (EMA) granted Orphan Drug Designation status to MRG-106 for the treatment of patients with CTCL.
miRagen Therapeutics’ MRG-106 is an inhibitor of miR-155, which is elevated in malignant T-cells. MiR-155 is a key player in a range of normal and malignant cell pathways and processes, and potentially contributes to CTCL cell progression and survival.
A phase I trial (NCT02580552) of MRG-106 in Mycosis Fungoides type CTCL (MF-CTCL) is currently being carried out; results will be presented during this year’s American Society of Clinical Oncology Annual Meeting, taking place in Chicago between 2nd–6th June.
MRG-106 also holds Orphan Drug Designation for Mycosis Fungoides type CTCL from the U.S. Food and Drug Administration (FDA), awarded in March 2017.
- Lymphoma News Today. EU Gives Orphan Drug Status to MRG-106 for Treating T-cell Skin Lymphomas. 2017 May 26. https://lymphomanewstoday.com/2017/05/26/eu-grants-orphan-drug-status-to-skin-lymphoma-therapy-mrg-106/. [Accessed 2017 May 30].
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
7 votes - 17 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox